Medicare AdvantagePrior AuthMedium impact
MA08.102g, Mogamulizumab-kpkc (Poteligeo®)
Independence Blue Cross·Oncology, Dermatology·Pharmacy
Effective date
Jul 1, 2025
We identified it
Jun 19, 2026
Summary
Policy MA08.102g establishes medical necessity criteria for Mogamulizumab-kpkc (Poteligeo®), a pharmacy benefit affecting how this medication is authorized and billed under Medicare Advantage plans. The billing team must understand the new coverage criteria to ensure claims meet medical necessity requirements and avoid denials.
Action Required
By July 1, 2025: Billing team and providers must review the complete MA08.102g policy criteria for Mogamulizumab-kpkc (Poteligeo®) authorization. Update billing system to flag claims for this HCPCS code J9301 for medical necessity verification before submission. Pharmacy staff and providers must document that patient meets all medical necessity criteria outlined in the policy. Add policy reference to prior authorization submission templates. Claims submitted without documented medical necessity meeting policy criteria will be denied by Medicare Advantage plans.